海新能科(300072.SZ):擬開展生物柴油推廣應用試點工作
格隆匯5月15日丨海新能科(300072.SZ)公佈,為貫徹新發展理念,加快能源綠色低碳轉型,拓展國內生物柴油的應用場景,探索建立可複製、可推廣的發展路徑、政策體系,逐步形成示範效應和規模效應,國家能源局於2023年組織了生物柴油推廣應用試點申報及評審工作,並於2024年04月02日至04月09日發佈《國家能源局綜合司關於公示生物柴油推廣應用試點的通知》,就“生物柴油推廣應用試點(公示稿)”進行了公示。
公司於2024年05月14日收到《關於開展生物柴油推廣應用試點工作的通知》,將按照通知及相關主管單位要求開展北京市海淀區生物柴油推廣應用試點及山東省日照市莒縣生物柴油推廣應用試點工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.